Posted on 22/06/2010 in Pharmaceutical Company Product News Gilead Sciences has published new clinical trial data illustrating the advantages of Cayston, its inhalation-based antibiotic treatment for cystic fibrosis sufferers with Pseudomonas aeruginosa.
According to the results of the phase III study, the drug was able to demonstrate non-inferiority to tobramycin inhalation solution in terms of mean percent change in forced expiratory volume in one second per cent predicted following 28 days of treatment.
This mean the Gilead therapy was able to meet one of its co-primary endpoints in the trial, while positive safety data was also recorded.
Dr Norbert Bischofberger, Gilead's executive vice-president of research and development and chief scientific officer, said there was a "significant unmet medical need" for a new treatment in this category.
He said: "Given the chronic nature of pseudomonal infection and the potential for antibiotic resistance, it is important that cystic fibrosis patients have multiple treatment options."
Earlier this month, the company announced the appointment of Dr John McHutchison as its liver disease therapeutics division's new senior vice-president.Other news stories from 22/06/2010
Read more in the Zenopa News Archive
How this news is generated
|
